Literature DB >> 31769344

Diagnosis and management of secondary-progressive multiple sclerosis: time for change.

Jiwon Oh1, Katayoun Alikhani2, Tania Bruno3, Virginia Devonshire4, Paul S Giacomini5, Fabrizio Giuliani6, Hamid R Nakhaipour7, Robyn Schecter7, Catherine Larochelle8.   

Abstract

Identifying the transition of relapsing-remitting multiple sclerosis (MS) to the secondary-progressive MS form remains a clinical challenge due to the gradual nature of the transition, superimposed relapses, the heterogeneous course of disease among patients and the absence of validated biomarkers and diagnostic tools. The uncertainty associated with the transition makes clinical care challenging for both patients and physicians. The emergence of new disease-modifying treatments for progressive MS and the increasing emphasis of nonpharmacological strategies mark a new era in the treatment of progressive MS. This article summarizes challenges in diagnosis and management, discusses novel treatment strategies and highlights the importance of establishing a clear diagnosis and instituting an interdisciplinary management plan in the care of patients with progressive MS.

Entities:  

Keywords:  biomarkers; disease-modifying therapy; inflammation; neuroprotective; secondary-progressive multiple sclerosis

Mesh:

Substances:

Year:  2019        PMID: 31769344     DOI: 10.2217/nmt-2019-0024

Source DB:  PubMed          Journal:  Neurodegener Dis Manag        ISSN: 1758-2024


  2 in total

1.  Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2020-10-27       Impact factor: 5.749

Review 2.  The Current Challenges for Drug Discovery in CNS Remyelination.

Authors:  Sonia Balestri; Alice Del Giovane; Carola Sposato; Marta Ferrarelli; Antonella Ragnini-Wilson
Journal:  Int J Mol Sci       Date:  2021-03-12       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.